Acta Scientific Agriculture (ASAG)(ISSN: 2581-365X)

Review Article Volume 4 Issue 7

Pharmacological Approaches to Investigate the Potential Herbal Medicine (Decoction) in Treating COVID-19

Reshma Kumari1* and Sanjay Kumar2

1Department of Botany and Microbiology, Gurukula Kangri Vishwavidhyalaya, Haridwar, India
2Department of Botany, Pt. Badridutt Pandey, Govt. P.G. College, Bageshwar, India

*Corresponding Author: Reshma Kumari, Department of Botany and Microbiology, Gurukula Kangri Vishwavidhyalaya, Haridwar, India.

Received: May 20, 2020; Published: June 30, 2020

Reprints View PDF Related Articles

×

Abstract

Since December 2019, COVID-19 infection is spreading rapidly throughout worldwide. Every virus has a unique structure, behavior and infectious agent to create infections. The ayurvedic herbal medicine that seem to work for other viral infections should be tested against COVID-19. Qingfei Paidu decoction, Shuanghuanglian oral liquid (SHL), Mahuang Gancao Ganjiang Decoction (MGGD) and licorice are remedies that officials in China have recommended against COVID-19. Simultaneously, an Ayush Ministry advisory suggested that drinking decoction (ginger, turmeric, tulsi leaves) as ‘home remedies’ to boost immune system against Covid-19 in India. Likewise, Barleria lupulina leaves decoction is also one of the potential candidates which may be helpful for the treatment of COVID-19.

Keywords: COVID-19; Decoction; SARS; Immunity; Treatment

×

References

  1. Zhu N., et al. “A novel coronavirus from patients with pneumonia in China, 2019”. New England Journal of Medicine (2020).
  2. Yin Y and Wunderink RG. “MERS, SARS and other coronaviruses as causes of pneumonia”. Respirology 23 (2018): 130-137.
  3. Gao Y and Liu Q. “The Epidemic Dynamics of 2019 Novel Coronavirus (2019-nCoV) Infections in China”. SSRN (2020).
  4. Wang D., et al. “Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China”. The Journal of the American Medical Association 323 (2020): 1061-1069.
  5. Pandey MM., et al. “Indian herbal drug for general healthcare: an overview”. The Internet Journal of Alternative Medicine 6 (2008): 3.
  6. Li W., et al. “Bats are natural reservoirs of SARS-like coronaviruses”. Science 310 (2005): 676-679.
  7. Li F., et al. “Structure of SARS coronavirus spike receptor-binding domain complexed with receptor”. Science 309 (2005): 1864-1868.
  8. Giovanetti M., et al. “The first two cases of 2019‐nCoV in Italy: Where they come from?” Journal of Medical Virology 92 (2020): 518-521.
  9. Paraskevis D., et al. “Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event”. Infection, Genetics and Evolution 79 (2020): 104212. 
  10. Banerjee A., et al. “Bats and coronaviruses”. Viruses 11 (2019): 41.
  11. Hampton T. “Bats may be SARS reservoir”. The Journal of the American Medical Association 294 (2005): 2291-2291.
  12. Ni L., et al. “Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19 in Wuhan”. Frontiers of Medicine (2020): 1-5.
  13. Wang C., et al. “Oseltamivir compared with the Chinese traditional therapy Maxingshigan-Yinqiaosan in the treatment of H1N1 influenza: a randomized trial”. Annals of Internal Medicine 155 (2011): 217-225.
  14. Liu N., et al. “The prevention and treatment of COVID-19 with Qingfei Paidu decoction in shanxi China”. TMR Modern Herbal Medicine (2020): 1.
  15. Chen L and Chen H. “Effect of mahuang gancao ganjiang decoction on fusion and fission of mitochondria and apoptosis of lymphocytes in mice under cold stress”. Evidence-Based Complementary and Alternative Medicine (2017).
  16. Isakbaeva ET., et al. “SARS-associated coronavirus transmission, United States”. Emerging Infectious Diseases 10 (2004): 225.
  17. Du CYQ., et al. “Yu Ping Feng San, an ancient Chinese herbal decoction, induces gene expression of anti‐viral proteins and inhibits neuraminidase activity”. Phytotherapy Research 29 (2015): 656-661.
  18. Jian G., et al. “Antiinflammatory and immunoregulatory effects of total glucosides of Yupingfeng powder”. Chinese Medical Journal 122 (2009): 1636-1641.
  19. Hou L and Xin H. “Progress in the study of immuno-pharmacology of yupingfeng powder”. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi= Chinese Journal of Integrated Traditional and Western Medicine 18 (1998): 701-703.
  20. Liang CM., et al. “A serum pharmacological study on the immunoregulatory effects of Yu Ping Feng pulvis in mice”. Shanghai Journal of Immunology 23 (2003): 385-388.
  21. Yang Yp., et al. “Inhibitory effect of Jiawei Yupingfeng decoction on thymocyte apoptosis in mice”. Chinese Journal of Integrated Traditional And Western Medicine 22 (2002): 698-700.
  22. Liu L-S., et al. “The effects and mechanism of Yinqiao Powder on upper respiratory tract infection”. International Journal of Biotechnology for Wellness Industries 4 (2015): 57-60.
  23. Wang WY and Yang J. “An overview of the thoughts and methods of epidemic prevention in ancient Chinese Medicine”. Jilin Journal of Traditional Chinese Medicine (Chin) 31 (2011): 197-199.
  24. Yang X-B., et al. “Fuzheng Kang’ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial”. Trials 16 (2015): 1-6.
  25. Wu W-y., et al. “Treatment of advanced non-small cell lung cancer with extracorporeal high frequency thermotherapy combined with Chinese medicine”. Chinese Journal of Integrative Medicine 16 (2010): 406-410.
  26. Yang X-B., et al. “Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: a retrospective case-control study”. Complementary Therapies in Medicine 22 (2014): 1010-1018.
  27. Wang S., et al. “Decoction of Chinese herbal medicine fuzheng kang-ai induces lung cancer cell apoptosis via STAT3/Bcl-2/Caspase-3 pathway”. Evidence-Based Complementary and Alternative Medicine (2018).
  28. Wang YX., et al. “Utilizing integrating network pharmacological approaches to investigate the potential mechanism of Ma Xing Shi Gan Decoction in treating COVID-19”. European Review for Medical and Pharmacological Sciences 24 (2020): 3360-3384.
  29. Pharmacopoeia Commission C. “Pharmacopoeia of the People's Republic of China”. Edition. Chemical Industry Press (2000).
  30. Poon PMK., et al. “Immunomodulatory effects of a traditional Chinese medicine with potential antiviral activity: a self-control study”. The American Journal of Chinese Medicine 34 (2006): 13-21.
  31. Zeng RC. “Clinical observations on 15 cases of spontaneous pneumothorax treated with baihe gujin decoction”. Zhong Xi Yi Jie He Za Zhi=Chinese Journal of Modern Developments in Traditional Medicine 6 (1986): 280.
  32. Kumari R., et al. “Antibacterial, antioxidant and Immuno-modulatory properties in extracts of Barleria lupulina Lindl”. BMC Complementary and Alternative Medicine 17 (2017): 484.
  33. Sur PK and Das PK. “Radio-protective and anti-clastogenic effects of Barleria lupulina Lindl. Extract against γ (gamma)-ray (1.2 Gy) induced mitotic chromosomal aberrations of laboratory mice Mus musculus and its effect on fish tumour induced after γirradiation”. Journal of Research in Biology 2 (2012): 439-447.
  34. Chomnawang MT., et al. “Antimicrobial effects of Thai medicinal plants against acne-inducing bacteria”. Journal of Ethnopharmacology 101 (2005): 330-333.
  35. Sawangjaroen N., et al. “The anti-amoebic activity of some medicinal plants used by AIDS patients in southern Thailand”. Parasitology Research 98 (2006): 588-592.
  36. Senger DR., et al. “Anti-inflammatory activity of Barleria lupulina: identification of active compounds that activate the Nrf2 cell defense pathway, organize cortical actin, reduce stress fibers, and improve cell junctions in microvascular endothelial cells”. Journal of Ethnopharmacology 193 (2016): 397-407.
  37. Suba V., et al. “Antiinflammatory, analgesic and antiperoxidative efficacy of Barleria lupulina Lindl. Extract”. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives 19 (2005): 695-699.
  38. Wanikiat P., et al. “The anti-inflammatory effects and the inhibition of neutrophil responsiveness by Barleria lupulina and Clinacanthus nutans extracts”. Journal of Ethnopharmacology 116 (2008): 234-244.
  39. Suba V., et al. “Antiulcer activity of methanol fraction of Barleria lupulina Lindl. in animal models”. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives 18 (2004a): 925-929.
  40. Suba V., et al. “Anti-diabetic potential of Barleria lupulina extract in rats”. Phytomedicine 11 (2004b): 202-205.
  41. Kumari R and Dubey RC. “HPTLC and GC-MS profile of Barleria lupulina Lindl extracts and their effect on enteric bacterial pathogens”. Journal of Applied Pharmacy 8 (2016a): 62-68.
  42. Moin S., et al. “In vitro callus production and antibacterial activity of Barleria lupulina lindl”. Asia-Pacific Journal of Molecular Biology and Biotechnology 20 (2012): 59-64.
  43. Pattanayak S., et al. “A comparative study of extract of succulent leaves of living plant with methanolic and aqueous extract of Berleria lupulina Lindl. against pathogenic microbes by disc diffusion and spectrophotometry”. Exploratory Animal And Medical Research 4 (2014): 148-157.
  44. Kumari R and Dubey RC. “Phytochemical analysis and antibacterial and cytotoxic properties of Barleria lupulina Lindl. Extracts”. Journal of Plant Pathology and Microbiology 7 (2016b): 2.
  45. Mazumder PM., et al. “Evaluation of antiarthritic and immunomodulatory activity of Barleria lupulina”. Asian Pacific Journal of Tropical Biomedicine 2 (2012): S1400-S1406.
  46. Tewtrakul S., et al. “Anti-HIV-1 protease-and HIV-1 integrase activities of Thai medicinal plants known as Hua-Khao-Yen”. Journal of Ethnopharmacology 105 (2006): 312-315.
  47. Rahmatullah RN., et al. “Barleria lupulina: A medicinal plant of Bangladesh: A review”. Journal of Medicinal Plants 6 (2018): 231-234.
  48. Liu J., et al. “Chinese herbal medicine for severe acute respiratory syndrome: a systematic review and meta-analysis”. Journal of Alternative and Complementary Medicine 10 (2004): 1041-1051.
  49. World Health O. SARS: clinical trials on treatment using a combination of traditional Chinese medicine and Western medicine: report of the WHO International Expert Meeting to review and analyse clinical reports on combination treatment for SARS, 8-10 October 2003, Beijing, People's Republic of China (2004).
  50. Xu J and Zhang Y. “Traditional Chinese medicine treatment of COVID-19”. Complementary Therapies in Clinical Practice (2020): 101165.
  51. Medicine NAoTC. Notice on recommending the use of "Qingfei Detox Decoction" in the treatment of new coronavirus-infected pneumonia with integrated Chinese and Western medicine (2020). 
  52. Chen X-T., et al. “Immunomodulating effects of fractioned polysaccharides isolated from Yu-Ping-Feng-Powder in cyclophosphamide-treated mice”. The American Journal of Chinese Medicine 34 (2006): 631-641.
  53. Lau JTF., et al. “The use of an herbal formula by hospital care workers during the severe acute respiratory syndrome epidemic in Hong Kong to prevent severe acute respiratory syndrome transmission, relieve influenza-related symptoms, and improve quality of life: a prospective cohort study”. Journal of Alternative and Complementary Medicine 11 (2005): 49-55.
×

Citation

Citation: Reshma Kumari and Sanjay Kumar. “Pharmacological Approaches to Investigate the Potential Herbal Medicine (Decoction) in Treating COVID-19". Acta Scientific Agriculture 4.7 (2020): 123-131.




Metrics

Acceptance rate32%
Acceptance to publication20-30 days
Impact Factor1.014

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"

Contact US









Creative Commons License Open Access by Acta Scientific is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at https://actascientific.com

ff

Acta Scientific Journals

ff

© 2024 Acta Scientific, All rights reserved.